Skip to search formSkip to main contentSkip to account menu

dulaglutide

National Institutes of Health

Related topics

Related topics

9 relations
0.5 ML dulaglutide 3 MG/ML Auto-InjectorGlucagon-Like Peptide 1analogs & derivatives

Broader (4)

Glucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Narrower (2)

LY 2189265Trulicity

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Improved Clinical Outcomes With Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs With or Without Insulin in Overweight Indian Patients With Type 2 Diabetes Mellitus: Retrospective Study in…
AIM Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated several extra-pancreatic benefits in addition to… 
2018
2018
Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch® among self-injection-naïve patients with type 2 diabetes mellitus in Japan
Abstract Objective: This study assessed training time with the dulaglutide single-use pen (SUP) and the insulin degludec… 
2018
2018
Renoprotective effects of dulaglutide in patients with T2DM and CKD
The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney… 
2018
2018
Improved Glycemic Control due to Reduction in Glucagon Levels by the Administration of Once-Weekly Dulaglutide in a Non-Obese Patient With Type 2 Diabetes
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is a cornerstone for the management of obesity and type 2… 
2017
2017
Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes
IntroductionThis analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in… 
Review
2016
Review
2016
Adjunctive Role of Glucagon‐Like Peptide‐1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are commonly used in combination with insulin to manage type 2 diabetes… 
2016
2016
Network meta‐analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are an established treatment for people with type 2 diabetes (T2D). We aimed to… 
2016
2016
[Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Dulaglutide (Trulicity®) is a new once-weekly agonist of Glucagon-Like Peptide-1 (GLP-1) receptors indicated in the treatment of… 
Review
2014
Review
2014
Dulaglutide for the treatment of type 2 diabetes.
Dulaglutide is a novel glucagon-like peptide 1 (GLP-1) receptor agonist with a unique structure that supports once-weekly dosing… 
2013
2013
Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)